Epidemiologia da anafilaxia no Brasil: Registro Brasileiro de Anafilaxia (RBA) da Associação Brasileira de Alergia e Imunologia (ASBAI)
Epidemiology of anaphylaxis in Brazil: The Brazilian Registry of Anaphylaxis (RBA) of the Brazilian Association of Allergy and Immunology (ASBAI)
Mara Morelo Rocha Felix; Dirceu Solé; Herberto José Chong-Neto; Ekaterini Simões Goudouris; Alexandra Sayuri Watanabe; Norma de Paula M. Rubini; Emanuel Sarinho; Fátima Rodrigues Fernandes; Fábio Chigres Kuschnir; Grupo Brasileiro de Interesse em Anafilaxia (GBIA)
Resumo
Introdução: A anafilaxia é uma reação alérgica multissistêmica grave, de início agudo e potencialmente fatal. Poucos são os dados sobre sua epidemiologia no Brasil. O Registro Brasileiro de Anafilaxia da Associação Brasileira de Alergia e Imunologia (RBAASBAI) teve como objetivo ampliar o conhecimento sobre anafilaxia em indivíduos brasileiros. Métodos: Estudo observacional transversal com questionário online sobre dados demográficos, desencadeantes suspeitos, manifestações clínicas, atendimento durante a reação, investigação diagnóstica e aconselhamento após a reação de pacientes que experimentaram uma reação anafilática. Resultados: Entre junho/2021 e abril/2023, foram incluídos 237 pacientes (131 femininos): 99 crianças/adolescentes; 127 adultos e 11 idosos. Houve predomínio de meninos entre crianças/ adolescentes (55,5%), e de mulheres entre os adultos (64,5%), e mediana de idade de 22 anos (< 1 a 77 anos). As manifestações cutâneas (92,8%) foram as mais frequentes, seguidas pelas respiratórias (70,1%), gastrointestinais (52,3%), neurológicas (36,3%) e cardiovasculares (35,3%). Os principais desencadeantes foram: alimentos (43,0%), medicamentos (26,2%), himenópteros (21,6%) e látex (2,5%); os alimentos entre crianças (leite, ovo, amendoim/ castanhas), e os fármacos (anti-inflamatórios e antibióticos) entre os adultos. Quanto ao tratamento, 61,1% recebeu adrenalina (52,7% por profissional e 8,4% via autoinjetor de adrenalina - AIA). Uma adolescente (12 anos) faleceu após picada de abelha. A maioria recebeu plano escrito de emergência (78,1%) e foi ensinada a usar o AIA (70%). Conclusão: Os alimentos foram os desencadeantes mais comuns entre crianças/adolescentes, e os fármacos entre adultos brasileiros. A adrenalina continua sendo subutilizada, reforçando a necessidade de maior disseminação do tratamento adequado da anafilaxia.
Palavras-chave
Abstract
Introduction: Anaphylaxis is a life-threatening, acute, severe multisystem allergic reaction. There is little data on its epidemiology in Brazil. The Brazilian Anaphylaxis Registry of the Brazilian Association of Allergy and Immunology (RBA-ASBAI) was devised to expand knowledge about anaphylaxis in Brazilian individuals. Methods: Cross-sectional observational study using an online questionnaire to collect data on demographics, suspected triggers, clinical manifestations, treatment during the reaction, diagnostic workup, and post-reaction counseling in patients who have experienced an anaphylactic reaction. Results: Between June 2021 and April 2023, 237 patients were included (131 female): 99 children/adolescents (<18yo), 127 adults (18-64yo), and 11 older adults (65-77yo). There was a male predominance in the pediatric group (55.5%), while females were predominant among adults (64.5%). The median age was 22 years (range, <1 to 77). The most frequent clinical manifestations were cutaneous (92.8%), followed by respiratory (70.1%), gastrointestinal (52.3%), neurological (36.3%), and cardiovascular (35.3%). The most common triggers were foods (43.0%), drugs (26.2%), venoms (21.6%), and latex (2.5%). Foods (milk, egg, peanuts/tree nuts) predominated among children, versus drugs (mostly nonsteroidal anti-inflammatory drugs and antibiotics) among adults. Regarding treatment, 61.1% received epinephrine (52.7% by a healthcare professional and 8.4% via epinephrine auto-injector [EAI]). One teenager (12yo) died due to a bee sting. Most patients received a written emergency plan (78.1%) and were taught how to use the EAI (70%). Conclusion: Foods were the most common triggers of anaphylaxis among Brazilian children and adolescents, while drugs predominated among adults. Epinephrine continues to be underused, highlighting the need for greater awareness of proper treatment of anaphylaxis.
Keywords
References
1. Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, et al.; European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022 Feb;77(2):357-377.
2. Motosue MS, Li JT, Campbell RL. Anaphylaxis: Epidemiology and Differential Diagnosis. Immunol Allergy Clin North Am. 2022 Feb;42(1):13-25.
3. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020 Oct 30;13(10):100472.
4. ASCIA Anaphylaxis Clinical Update [site na Internet]. Disponível em: https://www.allergy.org.au/images/stories/hp/info/ASCIA_HP_Clinical_Update_Anaphylaxis_Dec2016.pdf. Acessado em: fevereiro/2021.
5. Bernd LAG, Fleig F, Alves MB, Bertozzo R, Coelho M, Correia JC, et al. Anafilaxia no Brasil - Levantamento da ASBAI. Rev Bras Alerg Imunopatol 2010;33(5):190-8.
6. Sole D, Ivancevich JC, Borges MS, Coelho MA, Rosario NA, Ardusso LRF, et al. Anaphylaxis in Latin America: a report of the online Latin American survey on anaphylaxis (OLASA). Clinics (Sao Paulo). 2011;66(6):943-7.
7. Nunes FA, Zanini F, Braga CS, da Silva AL, Fernandes FR, Solé D, et al. Incidence, triggering factors, symptoms, and treatment of anaphylaxis in a pediatric hospital. World Allergy Organ J. 2022 Aug 21;15(9):100689.
8. Bastos PGA, Camelo-Nunes IC, Cocco RR, Solé D, Ensina LFC. Anaphylaxis: data from a patient registry in a specialized service. Arq Asma Alerg Imunol. 2019;3(2):168-76.
9. Tanno LK, Molinari N, Annesi-Maesano I, Demoly P, Bierrenbach Al. Anaphylaxis in Brazil between 2011 and 2019. Clin Exp Allergy. 2022;52(9):1071-8.
10. Gaspar A, Santos N, Faria E, Câmara R, Rodrigues-Alves R, Carrapatoso I, et al.; Portuguese Society of Allergology and Clinical Immunology (SPAIC) Anaphylaxis Interest Group. Anaphylaxis: A Decade of a Nationwide Allergy Society Registry. J Investig Allergol Clin Immunol. 2021 Feb 21;32(1):23-32.
11. Jeong K, Ye YM, Kim SH, Kim KW, Kim JH, Kwon JW, et al. A multicenter anaphylaxis registry in Korea: Clinical characteristics and acute treatment details from infants to older adults. World Allergy Organ J. 2020;13(8):100449.
12. Poziomkowska-Gesicka I, Kurek M. Clinical Manifestations and Causes of Anaphylaxis. Analysis of 382 Cases from the Anaphylaxis Registry in West Pomerania Province in Poland. Int J Environ Res Public Health. 2020 Apr 17;17(8):2787.
13. Edelman SM, Kukkonen AK, Mäkelä MJ. Eliciting allergens and treatment of anaphylaxis: Report of the finnish national anaphylaxis registry. Allergy. 2019 Oct;74(10):2010-13.
14. Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135(4):956-63.
15. Miles LM, Gabrielli S, Clarke AE, Morris J, Eisman H, Gravel J, et al. When and how pediatric anaphylaxis cases reach the emergency department: Findings from the Cross-Canada Anaphylaxis Registry. J Allergy Clin Immunol Pract. 2020;8(4):1406-9.
16. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). Allergy. 2014;69(10):1397-404.
17. Schraven SP, Mlynski R. Evaluation of Multicenter Registry Data. Laryngorhinootologie. 2019 Mar;98(S 01):S173-S196.
18. Kraft M, Knop MP, Renaudin JM, Scherer Hofmeier K, Pföhler C, Bilò MB, et al.; Network for Online Registration of Anaphylaxis (NORA). Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry. Allergy. 2020 Apr;75(4):901-10.
19. Jares EJ, Cardona V, Gómez RM, Bernstein JA, Rosario Filho NA, Cherrez-Ojeda I, et al. Latin American anaphylaxis registry. World Allergy Organ J. 2023;16(2):100748.
20. UK Anaphylaxis Registry [site na Internet]. Disponível em: https://www.bsaci.org/professional-resources/bsaci-registries/ukanaphylaxis-registry/. Acessado em: 10/12/2023.
21. ASBAI - Registro Brasileiro de Anafilaxia [site na Internet]. Disponível em: https://asbai.org.br/registro-brasileiro-de-anafilaxia/. Acessado em: 12/12/2023.
Submitted date:
02/25/2024
Accepted date:
02/29/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email